Company Long-Term Loans and Borrowings: vbivaccines.com (VBIV)

This VBIV price chart illustrates the dynamics of the biotech firm, which develops immunizing agents and implements energy-efficient methods for processing toxic residues. Long-term debt stands at 0.00, while VBI Vaccines Inc. (VBIV) maintains the position of its PreHevbrio drug by applying a flexible discount system for insurance organizations. The business strategy is based on strict adherence to bioethics, industrial personnel protection, and the minimization of environmental harm during production.

Long-term liabilities measure the aggregate of credit resources with maturities exceeding one year, determining the stability of the capital structure. Growth in this metric signals an increase in debt service costs and potential default risks. By analyzing the long-term debt indicator, an investor assesses the balance between financial leverage and operational stability. For VBI Vaccines Inc. (VBIV), these funds are critical for scaling regional production sites. Optimizing borrowings ensures the continuity of vaccine distribution, protecting export channels from logistical disruptions.